HRP20041213A2 - Postupci zaštite endotelnih i epitelnih stanica tijekom kemoterapije - Google Patents

Postupci zaštite endotelnih i epitelnih stanica tijekom kemoterapije

Info

Publication number
HRP20041213A2
HRP20041213A2 HR20041213A HRP20041213A HRP20041213A2 HR P20041213 A2 HRP20041213 A2 HR P20041213A2 HR 20041213 A HR20041213 A HR 20041213A HR P20041213 A HRP20041213 A HR P20041213A HR P20041213 A2 HRP20041213 A2 HR P20041213A2
Authority
HR
Croatia
Prior art keywords
endothelic
epithelical
procedures
protection
stations during
Prior art date
Application number
HR20041213A
Other languages
English (en)
Croatian (hr)
Inventor
Eissner G�nther
Holler Ernst
Original Assignee
Klinikum der Universit�t Regensburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klinikum der Universit�t Regensburg filed Critical Klinikum der Universit�t Regensburg
Publication of HRP20041213A2 publication Critical patent/HRP20041213A2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
HR20041213A 2002-05-31 2003-06-02 Postupci zaštite endotelnih i epitelnih stanica tijekom kemoterapije HRP20041213A2 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38411402P 2002-05-31 2002-05-31
US38743802P 2002-06-11 2002-06-11
PCT/EP2003/005753 WO2003101468A1 (en) 2002-05-31 2003-06-02 Method for the protection of endothelial and epithelial cells during chemotherapy

Publications (1)

Publication Number Publication Date
HRP20041213A2 true HRP20041213A2 (hr) 2006-04-30

Family

ID=29715309

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20041213A HRP20041213A2 (hr) 2002-05-31 2003-06-02 Postupci zaštite endotelnih i epitelnih stanica tijekom kemoterapije

Country Status (16)

Country Link
EP (1) EP1509235A1 (is)
JP (1) JP2005527636A (is)
CN (1) CN1304011C (is)
AU (1) AU2003238189A1 (is)
CA (1) CA2487171A1 (is)
EA (1) EA008213B1 (is)
HR (1) HRP20041213A2 (is)
IL (1) IL165353A0 (is)
IS (1) IS7548A (is)
MX (1) MXPA04011941A (is)
NO (1) NO20045655L (is)
NZ (1) NZ536864A (is)
PL (1) PL374402A1 (is)
RS (1) RS102504A (is)
UA (1) UA83628C2 (is)
WO (1) WO2003101468A1 (is)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20031714A1 (it) 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
EP2637672B1 (en) * 2010-11-12 2018-08-22 Gentium S.r.l. Defibrotide for use in prophylaxis and/or treatment of graft versus host disease (gvhd).
ES2660969T5 (es) 2012-06-22 2021-09-03 Gentium S R L Método basado en euglobulina para determinar la actividad biológica de defibrotida
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU754242B2 (en) * 1997-04-28 2002-11-07 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof

Also Published As

Publication number Publication date
MXPA04011941A (es) 2005-07-26
CN1655801A (zh) 2005-08-17
NO20045655L (no) 2004-12-27
PL374402A1 (en) 2005-10-17
NZ536864A (en) 2008-08-29
WO2003101468A1 (en) 2003-12-11
JP2005527636A (ja) 2005-09-15
EA200401448A1 (ru) 2005-06-30
IL165353A0 (en) 2006-01-15
AU2003238189A1 (en) 2003-12-19
IS7548A (is) 2004-11-24
EP1509235A1 (en) 2005-03-02
UA83628C2 (ru) 2008-08-11
CN1304011C (zh) 2007-03-14
CA2487171A1 (en) 2003-12-11
RS102504A (sr) 2006-12-15
EA008213B1 (ru) 2007-04-27

Similar Documents

Publication Publication Date Title
ZA202308118B (en) Cdk inhibitor
MXPA05013642A (es) Composicion de un antagonista de vegf y un agente antiproliferativo y su uso para el tratamiento de cancer.
BRPI0413427A (pt) derivados de piridilpirrol ativos como inibidores da cinase
BRPI0409128A (pt) uso de antagonistas de opióides periféricos, especialmente metilnaltrexona para tratar sìndrome de intestino irritável
CY1115289T1 (el) Μεθοδοι αγωγης εναντι ασθενειας που σχετιζεται με φλεγμονη
DK1551409T3 (da) Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
MY141119A (en) Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
ATE408601T1 (de) Fredericamycin-derivate
SV2009003283A (es) Inhibidores de la actividad de la akt
TW200631578A (en) Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
PH12021550965A1 (en) Combination therapy for treatment of hematological diseases
GB0222514D0 (en) Organic compounds
MXPA05004697A (es) Soluciones farmaceuticas que comprenden un compuesto modafinil y uso para la fabricacion de un medicamento para tratar diferentes enfermedades.
PA8599701A1 (es) Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr
TW200616608A (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
NO20024646L (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
ECSP045397A (es) 6-ALQUILIDEN-PENEMS BICÍCLICOS COMO INHIBIDORES DE LAS b-LACTAMASAS
CR8603A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
HRP20041213A2 (hr) Postupci zaštite endotelnih i epitelnih stanica tijekom kemoterapije
ECSP045405A (es) Penems 6-alquiliden heterotriciclil como inhibidores de la beta lactamasa
ATE349221T1 (de) Extrakt mit antitumoraler und antitoxischer wirkung
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
NO20064753L (no) Kombinasjonsterapi

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20090521

Year of fee payment: 7

OBST Application withdrawn